Literature DB >> 30076112

Pain Management Issues as Part of the Comprehensive Care of Patients with Sickle Cell Disease.

Bhaskar V K S Lakkakula1, Radharani Sahoo2, Henu Verma2, Saikrishna Lakkakula3.   

Abstract

BACKGROUND: Vaso-occlusive pain crisis is one of the primary complications of sickle cell disease (SCD) and is responsible for the majority of hospital visits in patients with SCD. Stints of severe pain can last for hours to days and are difficult to treat and manage, often resulting in drastically reduced quality of life.
PURPOSE: Our purpose is to provide an overview of pain management issues in SCD populations.
METHODS: We explored literature using PubMed and Embase for the etiology and management of pain in SCD. Databases were searched employing the following terms: sickle cell, pain pathways, pain perception, pharmacological therapies, psychological therapies, physical therapies and genetics.
RESULTS: Pain in SCD can vary from acute to chronic (persistent) or mixed and understanding of the underlying mechanisms is important for proper pain management. Currently, there are many means of managing pain in children with SCD, which involve pharmacological and non-pharmacological approaches. A combination of psychotherapy and pain medications can be used for treatment of pain and other psychosocial co-morbidities in complex persistent pain.
CONCLUSIONS: Providing more appropriate medication and optimal dosage based on individual's genomic variations is the future of medicine, and this will allow the physicians to hone in on optimal pain management in patients with SCD.
Copyright © 2018 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30076112     DOI: 10.1016/j.pmn.2018.06.004

Source DB:  PubMed          Journal:  Pain Manag Nurs        ISSN: 1524-9042            Impact factor:   1.929


  4 in total

Review 1.  Erythrocyte microRNAs: a tiny magic bullet with great potential for sickle cell disease therapy.

Authors:  Henu Kumar Verma; Yashwant Kumar Ratre; L V K S Bhaskar; Raffaella Colombatti
Journal:  Ann Hematol       Date:  2021-01-04       Impact factor: 3.673

2.  Improving Pain Assessment Using Vital Signs and Pain Medication for Patients With Sickle Cell Disease: Retrospective Study.

Authors:  Swati Padhee; Gary K Nave; Tanvi Banerjee; Daniel M Abrams; Nirmish Shah
Journal:  JMIR Form Res       Date:  2022-06-23

3.  Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC).

Authors:  Caroline Conceição da Guarda; Sètondji Cocou Modeste Alexandre Yahouédéhou; Rayra Pereira Santiago; Joelma Santana Dos Santos Neres; Camila Felix de Lima Fernandes; Milena Magalhães Aleluia; Camylla Vilas Boas Figueiredo; Luciana Magalhães Fiuza; Suellen Pinheiro Carvalho; Rodrigo Mota de Oliveira; Cleverson Alves Fonseca; Uche Samuel Ndidi; Valma Maria Lopes Nascimento; Larissa Carneiro Rocha; Marilda Souza Goncalves
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

Review 4.  Moving Toward a Multimodal Analgesic Regimen for Acute Sickle Cell Pain with Non-Opioid Analgesic Adjuncts: A Narrative Review.

Authors:  Martha O Kenney; Wally R Smith
Journal:  J Pain Res       Date:  2022-03-31       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.